AnaptysBio, Inc.

How big is AnaptysBio, Inc.?

As of Jun 18, AnaptysBio, Inc. has a market capitalization of 699.84 million and reported net sales of 111.87 million with a net profit of -140.62 million over the latest four quarters. Shareholder's funds are 70.87 million, and total assets amount to 483.83 million.

As of Jun 18, AnaptysBio, Inc. has a market capitalization of 699.84 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 111.87 million, while the sum of net profit for the same period is -140.62 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 70.87 million, and the total assets amount to 483.83 million.

What does AnaptysBio, Inc. do?

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody products for inflammation and immuno-oncology. It has a market cap of approximately $699.84 million, with recent net sales of $28 million and a net loss of $39 million.

Overview:<BR>AnaptysBio, Inc. is a clinical-stage biotechnology company engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 28 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -39 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 699.84 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.22 <BR>Return on Equity: -413.34% <BR>Price to Book: 20.57<BR><BR>Contact Details:<BR>Address: 10421 Pacific Center Ct Ste 200, SAN DIEGO CA: 92121-4339 <BR>Tel: 1 858 3626295 <BR>Fax: 1 858 3626296 <BR>Website: https://www.anaptysbio.com/

Who are in the management team of AnaptysBio, Inc.?

As of March 2022, AnaptysBio, Inc.'s management team includes Dr. James Topper (Independent Chairman), Mr. Hamza Suria (President and CEO), and several independent directors, including Mr. Hollings Renton, Dr. Magda Marquet, Dr. Dennis Fenton, Ms. Laura Hamill, and Mr. John Schmid.

As of March 2022, the management team of AnaptysBio, Inc. includes the following individuals:<BR><BR>- Dr. James Topper, who serves as the Independent Chairman of the Board.<BR>- Mr. Hamza Suria, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Hollings Renton, who holds the position of Lead Independent Director.<BR>- Dr. Magda Marquet, who is a Director.<BR>- Dr. Dennis Fenton, who serves as an Independent Director.<BR>- Ms. Laura Hamill, who is also an Independent Director.<BR>- Mr. John Schmid, who is another Independent Director.<BR><BR>In summary, the management team is led by Dr. James Topper and Mr. Hamza Suria, with additional directors providing oversight and governance.

Should I buy, sell or hold AnaptysBio, Inc.?

Is AnaptysBio, Inc. overvalued or undervalued?

As of March 7, 2022, AnaptysBio, Inc. is considered risky and overvalued with a Price to Book Value of 20.47 and an EV to Sales ratio of 6.16, indicating significant operational challenges compared to peers like Alector, Inc. and Entrada Therapeutics, Inc.

As of 7 March 2022, the valuation grade for AnaptysBio, Inc. moved from fair to risky, indicating a more cautious outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 20.47 and an EV to Sales ratio of 6.16, which suggest a premium valuation despite the lack of profitability. Additionally, the EV to EBITDA ratio stands at -7.04, reflecting significant operational challenges.<BR><BR>In comparison to its peers, AnaptysBio's valuation ratios are less favorable; for instance, Alector, Inc. has an EV to EBITDA of 0.0787, while Entrada Therapeutics, Inc. shows a more manageable EV to EBITDA of 1.6353. These comparisons highlight AnaptysBio's relative overvaluation in the current market. Although specific return data is not available, the lack of positive performance metrics reinforces the notion that the company is not positioned favorably against broader market benchmarks like the S&P 500.

Is AnaptysBio, Inc. technically bullish or bearish?

As of October 3, 2025, AnaptysBio, Inc. shows a bullish technical trend, supported by strong MACD and moving averages, despite some mixed signals from Bollinger Bands and KST indicators.

As of 3 October 2025, the technical trend for AnaptysBio, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, and daily moving averages also indicate a bullish stance. While Bollinger Bands show a mildly bullish trend on both weekly and monthly levels, the KST is mildly bearish on both time frames. The Dow Theory indicates a mildly bullish trend on a monthly basis, while the OBV is bullish monthly but shows no trend weekly. Overall, the current technical stance is bullish, supported by strong MACD and moving average indicators. However, multi-period return data is not available for comparison with the S&P 500.